For Immediate Release

Chicago, IL – November 13, 2009 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Stryker Corp. (SYK), Synergetics USA, Inc. (SURG), Zimmer Holdings (ZMH), Conmed Corporation (CNMD) and Smith & Nephew (SNN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Thursday’s Analyst Blog:

Stryker Strikes Acquisition Deals

Stryker Corp. (SYK) is on a takeover spree having made three acquisitions recently. The company acquired OtisMed Corp., Mutoh Co. Ltd. and certain of its affiliates, and Synergetics USA, Inc. (SURG). Financial terms of these transactions include $67 million in upfront payment as well as potential future milestone and royalty payments of up to $36 million. These acquisitions are expected to be completed by the end of 2009.

OtisMed Corp. is a privately held software technology firm that focuses on customizable instrumentation complementing Stryker’s Triathlon Knee System, as well as other Stryker implants. Stryker will incorporate OtisMed as part of its Orthopaedics division.

Mutoh Co. Ltd. is a Japanese company and a leading provider of equipment, products, instruments and services to the medical and scientific communities. On the other hand, Synergetics USA, Inc. is a leading supplier of precision microsurgery instrumentation.

Mutoh and Synergetics acquisitions give Stryker access to different assets used to produce Sonopet Ultrasonic Aspirator control consoles, hand pieces and accessories as well as the rights to market and sell these products globally. Post the completion of the acquisition, Stryker will incorporate these two companies into its Instruments division.

The acquisitions widen Stryker’s product portfolio and will boost its top-line. Stryker is one of the world’s largest medical device companies operating in the global orthopedic market. In the orthopedic space, Stryker faces competition from major players like Zimmer Holdings (ZMH), Conmed Corporation (CNMD) and Smith & Nephew (SNN).

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks “Profit from the Pros” e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Mark Vickery
Web Content Editor



Zacks Investment Research